SEC Comment Letter 0000000000-24-009235 to Humacyte, Inc. (HUMA)

Humacyte, Inc.
Date: Aug. 13, 2024 · CIK: 0001818382 · Accession: 0000000000-24-009235

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-39532

Date

August 13, 2024

Author

Dale Sander

Form

UPLOAD

Company

Humacyte, Inc.

Letter

August 13, 2024 Dale Sander Chief Financial Officer Humacyte, Inc. 2525 East North Carolina Hwy 34 Durham, NC 27713 Re:Humacyte, Inc. Form 10-K for the Year Ended December 31, 2023 Filed March 28, 2024 File No. 001-39532 Dear Dale Sander: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

August 13, 2024
Dale Sander
Chief Financial Officer
Humacyte, Inc.
2525 East North Carolina Hwy 34
Durham, NC 27713
Re:Humacyte, Inc.
Form 10-K for the Year Ended December 31, 2023
Filed March 28, 2024
File No. 001-39532
Dear Dale Sander:
            We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io